Muscle Loss: What Could Be Causing It?

What Is Muscle Loss and Why Does the Cause Matter So Much?

Muscle loss is not a single disease. It is a symptom with a long differential diagnosis, and the label attached to it changes the treatment entirely. Sarcopenia refers specifically to age-related muscle decline. Cachexia describes the inflammatory, metabolic muscle wasting tied to chronic illness. Myopathy means the muscle fiber itself is diseased. Disuse atrophy is what happens when a limb is immobilized. Getting the label right before starting treatment is not optional.

Why Misdiagnosis Is Common

Patients and clinicians alike tend to attribute muscle loss to aging or "not eating enough." That explanation fits fewer cases than expected. A 2018 systematic review in Age and Ageing found sarcopenia prevalence ranges from 1% to 29% depending on the population studied, and a substantial proportion of cases identified in community-dwelling adults had an identifiable, treatable secondary cause that had been missed [1].

The Financial and Functional Cost

Sarcopenia-related disability costs the U.S. Healthcare system an estimated $18.5 billion per year, based on a landmark 2000 analysis by Janssen et al. Published in the Journal of the American Geriatrics Society [2]. Beyond cost, low muscle mass independently predicts surgical complications, fall-related fractures, and all-cause mortality.

Cause 1: Normal Aging (Sarcopenia)

Age-related muscle loss begins around age 40 and accelerates after 60. The European Working Group on Sarcopenia in Older People (EWGSOP2) defines sarcopenia as low muscle strength plus low muscle quantity or quality, and classifies it as severe when physical performance also falls [3].

Rate of Decline

Muscle mass decreases at roughly 1 to 2% per year after age 50 and muscle strength at 1.5 to 5% per year, according to data synthesized in the American Journal of Clinical Nutrition [4]. Men start from a higher baseline but lose muscle faster in absolute terms than women.

What Drives It Biologically

Three overlapping mechanisms accelerate age-related atrophy: declining anabolic hormones (testosterone, IGF-1, DHEA), low-grade chronic inflammation mediated by IL-6 and TNF-alpha, and reduced satellite cell regenerative capacity. Each of these can be partially addressed, which is why sarcopenia is no longer considered purely inevitable.

EWGSOP2 Diagnostic Cutoffs

The EWGSOP2 guideline recommends grip strength <27 kg in men and <16 kg in women as the primary screening tool, followed by DXA or BIA to confirm low appendicular lean mass [3]. Gait speed <0.8 m/s or a Short Physical Performance Battery score <8 confirms severe sarcopenia.

Cause 2: Hypogonadism and Sex Hormone Deficiency

Low testosterone in men and estrogen deficiency in women are among the most commonly missed reversible causes of muscle loss in adults under 65. Testosterone directly stimulates muscle protein synthesis via androgen receptors in myocytes. Estrogen has a separate, underappreciated role in satellite cell activation and muscle repair.

Male Hypogonadism

Total testosterone below 300 ng/dL on two morning measurements meets the Endocrine Society's threshold for male hypogonadism [5]. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, confirmed that testosterone replacement therapy (TRT) significantly increased lean mass and reduced fat mass compared to placebo over 22 months [6]. Mean appendicular lean mass increased by 1.1 kg in the TRT group versus 0.3 kg in placebo (P<0.001).

Female Hormone Deficiency

Women lose roughly 10% of muscle mass in the first five years after menopause, in part because estradiol decline reduces IGF-1 sensitivity. A 2021 review in Menopause confirmed that menopausal hormone therapy attenuates but does not fully prevent this loss, and that the effect is greatest when therapy begins within five years of the final menstrual period [7].

Cause 3: Cachexia From Chronic Disease

Cachexia is distinct from simple malnutrition. It involves a cytokine-driven catabolic state in which muscle protein is broken down faster than it can be synthesized, even when caloric intake is adequate. Cancer, heart failure, COPD, chronic kidney disease, and HIV all cause cachexia through overlapping inflammatory pathways.

Cancer Cachexia

The international consensus definition, published in Lancet Oncology in 2011, requires unintentional weight loss >5% over six months, or BMI <20 with any weight loss, or appendicular skeletal muscle index below 7.26 kg/m² in men (5.45 in women) [8]. Pancreatic and gastric cancers carry the highest cachexia rates, affecting up to 85% of patients.

Cardiac and Renal Cachexia

Cardiac cachexia affects 10 to 15% of patients with chronic heart failure and carries a 50% 18-month mortality rate, per a review in the Journal of the American College of Cardiology [9]. In chronic kidney disease, uremic toxins suppress muscle protein synthesis while metabolic acidosis accelerates proteolysis. Correcting acidosis with oral sodium bicarbonate (0.5 to 1.0 mEq/kg/day) has been shown to slow muscle wasting in stage 3 to 4 CKD in a randomized trial published in the Journal of the American Society of Nephrology [10].

Cause 4: Thyroid Disorders

Both hypothyroidism and hyperthyroidism cause muscle loss, through opposite mechanisms. Hypothyroidism slows protein turnover and causes myopathy characterized by proximal weakness, elevated creatine kinase, and myoedema on percussion. Hyperthyroidism accelerates proteolysis and increases the rate of muscle breakdown faster than synthesis can compensate.

Diagnosis

A TSH outside the 0.4 to 4.0 mIU/L reference range with corroborating free T4 is sufficient to implicate the thyroid. The American Thyroid Association guidelines recommend checking TSH in any patient with unexplained proximal muscle weakness [11]. Creatine kinase is elevated in up to 90% of patients with overt hypothyroid myopathy.

Treatment Response

Muscle strength and mass recover substantially within 6 to 12 months of achieving euthyroid status with levothyroxine, though some patients over 60 retain mild residual weakness. This recovery trajectory distinguishes thyroid myopathy from primary muscle disease.

Cause 5: Glucocorticoid Excess (Cushing Syndrome or Steroid Myopathy)

Exogenous corticosteroids and endogenous cortisol excess both cause preferential type IIb fast-twitch muscle fiber atrophy. Patients typically report proximal weakness before they notice visible muscle loss. Prednisolone at doses above 10 mg/day for more than four weeks carries a clinically meaningful risk of steroid myopathy.

Endogenous Cushing syndrome, caused by pituitary adenoma (Cushing disease), adrenal tumor, or ectopic ACTH, affects approximately 3 per million people per year. The diagnosis requires 24-hour urinary free cortisol, late-night salivary cortisol, or 1 mg overnight dexamethasone suppression test, per Endocrine Society guidelines available at endocrine.org [12].

Muscle loss from exogenous steroids begins to reverse within 4 to 6 weeks of dose reduction. Exercise, particularly resistance training, attenuates steroid-induced atrophy even when the steroid cannot be discontinued.

Cause 6: Malnutrition and Inadequate Protein Intake

Protein-energy malnutrition causes muscle loss by simple substrate deficiency. The body catabolizes skeletal muscle to supply amino acids for hepatic gluconeogenesis and immune function during caloric restriction. This mechanism also explains why aggressive caloric restriction without adequate protein intake, including some very low-calorie diets used for weight loss, accelerates lean mass loss.

Protein Targets

The Recommended Dietary Allowance of 0.8 g/kg/day is a minimum to prevent deficiency, not an optimal target for preserving muscle. A meta-analysis of 49 trials published in the British Journal of Sports Medicine found that protein supplementation significantly increased lean mass and strength gains from resistance training, with effects plateauing at approximately 1.62 g/kg/day [13].

GLP-1 Agonist Considerations

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) produce significant weight loss, but a portion of that weight is lean mass. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean total body weight loss at 68 weeks versus 2.4% with placebo [14]. Approximately 39% of the weight lost was lean tissue, based on body composition substudies published in Obesity [15]. Patients on GLP-1 therapy should be counseled to consume at least 1.2 g protein/kg/day and perform resistance training to protect lean mass.

Cause 7: Inflammatory Myopathies

Polymyositis, dermatomyositis, and inclusion body myositis are autoimmune conditions in which immune cells directly attack muscle fibers. All three present with proximal weakness, but inclusion body myositis characteristically also involves distal hand and finger flexor weakness, which is atypical for the others.

Diagnostic Workup

Elevated creatine kinase (often 10 to 50 times the upper limit of normal), positive ANA, anti-Jo-1, or anti-Mi-2 antibodies, and MRI showing muscle edema support the diagnosis. Muscle biopsy remains the gold standard. Per the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria, published in Annals of the Rheumatic Diseases, a score of >7.5 points gives a probability of >90% for inflammatory myopathy [16].

Treatment

High-dose prednisone (1 mg/kg/day, maximum 80 mg) is first-line for polymyositis and dermatomyositis. Methotrexate or azathioprine are added as steroid-sparing agents within the first 4 to 8 weeks. Inclusion body myositis does not respond meaningfully to immunosuppression, which is a key distinguishing clinical feature.

Cause 8: Neurological Causes

Muscle is only as healthy as its nerve supply. Motor neuron diseases (ALS, spinal muscular atrophy), peripheral neuropathies (diabetic, hereditary), and nerve root compression from disc herniation all cause neurogenic atrophy. The pattern of weakness provides the first diagnostic clue: distal greater than proximal in peripheral neuropathy, asymmetric in radiculopathy, and fasciculation-dominant in motor neuron disease.

Electromyography

Electromyography (EMG) and nerve conduction studies (NCS) differentiate myopathic from neuropathic atrophy with high accuracy. Myopathic patterns show small, polyphasic motor unit potentials; neuropathic patterns show large, reinnervated units and reduced recruitment. The American Academy of Neurology supports EMG/NCS as the primary electrodiagnostic tool in unexplained weakness or atrophy [17].

Cause 9: Disuse Atrophy

Muscle loss from immobilization begins within 24 hours of bed rest and progresses at 0.5 to 0.6% of muscle mass per day during strict immobility, according to a bed-rest study published in the Journal of Applied Physiology [18]. Ten days of bed rest in adults over 70 produces the same lean mass loss that would otherwise take a full year of normal aging. This makes early mobilization after surgery or illness a genuine clinical priority.

Disuse atrophy is fully reversible with progressive loading, provided the underlying nerve supply is intact. Recovery typically takes two to three times as long as the period of immobilization.

How Muscle Loss Is Diagnosed: A Stepwise Approach

No single test diagnoses muscle loss and its cause simultaneously. The following four-step framework, developed by the HealthRX medical team for use in telehealth evaluations, organizes the workup by yield and cost:

Step 1: Confirm That Muscle Loss Is Real

Grip dynamometry (cutoffs: <27 kg men, <16 kg women) or DXA-derived appendicular lean mass index (<7.0 kg/m² men, <5.5 kg/m² women) confirms that measurable muscle deficiency exists, separating it from subjective weakness without atrophy.

Step 2: Screen for Common Reversible Causes

Order simultaneously: total testosterone (8 a.m. Draw), TSH, free T4, serum cortisol, CRP, ESR, creatine kinase, CBC, comprehensive metabolic panel, albumin, and 25-hydroxyvitamin D. This panel costs $150, $300 through most commercial labs and rules in or out the majority of treatable causes in a single draw.

Step 3: Targeted Imaging or Specialized Testing

If creatine kinase is above 1,000 U/L, order MRI of affected muscle groups. If TSH is suppressed or elevated, add thyroid antibodies. If cortisol is elevated, proceed to 24-hour urine free cortisol. If EMG is needed, refer to neurology.

Step 4: Muscle Biopsy

Reserve biopsy for cases where the inflammatory myopathy panel is positive, where myopathy is suspected but cause remains unclear after steps 1 to 3, or where inclusion body myositis is on the differential.

Treatment: What the Evidence Supports

Treatment of muscle loss depends entirely on cause, but several interventions have cross-cutting benefit regardless of etiology.

Resistance Training

Progressive resistance training three times per week is the single intervention with the broadest evidence base across all causes of muscle loss. A Cochrane review of 121 trials found resistance exercise increased lean mass and strength in older adults with sarcopenia, with an effect size of 0.84 for grip strength (95% CI 0.57 to 1.11) [19]. Sessions should include compound lower-body movements (squats, leg press) and pull-pattern upper-body movements at 70 to 85% of one-repetition maximum.

Protein and Leucine

Leucine-enriched protein supplements (at least 3 g leucine per serving) maximally stimulate muscle protein synthesis via mTORC1. The PROT-AGE Study Group, writing in the Journal of the American Medical Directors Association, recommended 1.0 to 1.2 g/kg/day for healthy older adults and 1.2 to 1.5 g/kg/day for those with acute or chronic illness [20].

Testosterone Replacement Therapy

For men with confirmed hypogonadism, TRT produces consistent lean mass gains of 1.5 to 3.0 kg over 12 months. The Endocrine Society's 2018 Clinical Practice Guideline recommends starting with testosterone enanthate 150 to 200 mg IM every 2 weeks, or transdermal testosterone 1.62% gel 40.5 to 81 mg/day, targeting a mid-normal serum testosterone of 400 to 700 ng/dL [5].

Treating the Underlying Disease

Cachexia does not respond reliably to nutrition alone when the inflammatory driver (tumor, heart failure, COPD exacerbation) is still active. Megestrol acetate 800 mg/day improves appetite and may modestly increase body weight in cancer cachexia, though lean mass gains are inconsistent per a Cochrane review [21]. Anamorelin, a ghrelin receptor agonist, increased lean body mass by 1.10 kg versus placebo in the ROMANA-1 trial (N=484) of non-small cell lung cancer patients, published in Lancet Oncology [22].

When to Seek Urgent Care

Unintentional loss of 5% or more of total body weight over six months, rapidly progressive weakness over days to weeks, dysphagia, fasciculations at rest, bilateral leg weakness, or CK above 10,000 U/L all warrant urgent evaluation rather than watchful waiting. Rhabdomyolysis, Guillain-Barre syndrome, and acute inflammatory myopathy can each be life-threatening if the diagnosis is delayed.

The Endocrine Society states that "measurement of serum testosterone should be performed in men presenting with signs or symptoms of testosterone deficiency, including decreased muscle mass and strength" [5]. In practice, fewer than 40% of men with symptomatic hypogonadism are tested at their first clinical encounter, a diagnostic gap that delays effective treatment by an average of 2.4 years based on claims data reviewed internally by the HealthRX medical team.